Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies

Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies

US Patent 8048880 · Granted Nov 1, 2011

Estimated economic value: $4,527,000 ⓘ

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of using buffered formulations of exendin (9-39)2023
Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof2021
Buffered formulations of exendin (9-39)2021
Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors2009
Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors2009
Phospholipase inhibitors2007
Phospholipase inhibitors2007
Chromogenic compound2002
Method for screening for non-tetracycline efflux pump inhibitors1999
Benzothiophenes for inhibiting hyperlipidemia1999
Potentiators of antibacterial agents1999
Recombinant beta-lactamase, usable as carrier molecule in immunogenic compositio1998